Ankle-Brachial Index and cardiovascular events in atrial fibrillation

Francesco Violi; Giovanni Davi; Marco Proietti; Daniele Pastori; William R. Hiatt; Gino Roberto Corazza; Francesco Perticone; Pasquale Pignatelli; Alessio Farcomeni; Anna Rita Vestri; Gregory Y. H. Lip; Stefania Basili; The ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators; on Behalf of

doi:10.1160/TH15-07-0612

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 115(04): 856-863
DOI: 10.1160/TH15-07-0612

Atherosclerosis and Ischaemic Disease

Schattauer GmbH

Ankle-Brachial Index and cardiovascular events in atrial fibrillation

The ARAPACIS Study

Authors

Francesco Violi

¹I Clinica Medica, Sapienza-University of Rome, Rome, Italy
Giovanni Davi

²Internal Medicine, University Of Chieti, Chieti, Italy
Marco Proietti

³University of Birmingham, Institute of Cardiovascular Sciences, Birmingham, UK
Daniele Pastori

¹I Clinica Medica, Sapienza-University of Rome, Rome, Italy
William R. Hiatt

⁴University of Colorado School Of Medicine, Division of Cardiology, Aurora, Colorado, USA
Gino Roberto Corazza

⁵First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Francesco Perticone

⁶Deparment of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy
Pasquale Pignatelli

¹I Clinica Medica, Sapienza-University of Rome, Rome, Italy
Alessio Farcomeni

⁷Department of Public Health and Infectious Disease, Sapienza-University of Rome, Rome, Italy
Anna Rita Vestri

⁷Department of Public Health and Infectious Disease, Sapienza-University of Rome, Rome, Italy
Gregory Y. H. Lip

³University of Birmingham, Institute of Cardiovascular Sciences, Birmingham, UK

⁸Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Stefania Basili

¹I Clinica Medica, Sapienza-University of Rome, Rome, Italy

The ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators

Abstract

Summary

Atrial fibrillation (AF) patients are at high risk for thrombotic and vascular events related to their cardiac arrhythmia and underlying systemic atherosclerosis. Ankle-Brachial Index (ABI) is a non-invasive tool in evaluating systemic atherosclerosis, useful in predicting cardiovascular events in general population; no data are available in AF patients. ARAPACIS is a prospective multicentre observational study performed by the Italian Society of Internal Medicine, analysing association between low ABI (≤0.90) and vascular events in NVAF out- or in-patients, enrolled in 136 Italian centres. A total of 2,027 non-valvular AF (NVAF) patients aged > 18 years from both sexes followed for a median time of 34.7 (interquartile range: 22.0–36.0) months, yielding a total of 4,614 patient-years of observation. Mean age was 73 ± 10 years old with 55% male patients. A total of 176 patients (8.7%) experienced a vascular event, with a cumulative incidence of 3.81%/patient-year. ABI≤ 0.90 was more prevalent in patients with a vascular event compared with patients free of vascular events (32.2 vs 20.2%, p< 0.05). On Cox proportional hazard analysis, ABI≤ 0.90 was an independent predictor of vascular events (hazard ratio (HR): 1.394, 95% confidence interval (CI): 1.042–1.866; p=0.02), vascular death (HR: 2.047, 95% CI: 1.255-3.338; p=0.004) and MI (HR: 2.709, 95%> CI: 1.485-5.083; p=0.001). This latter association was also confirmed after excluding patients with previous MI (HR: 2.901, 95% CI: 1.408-5.990, p=0.004). No association was observed between low ABI and stroke/transient ischaemic attack (p=0.91). In conclusion, low ABI is useful to predict MI and vascular death in NVAF patients and may independently facilitate cardiovascular risk assessment in NVAF patients.

Note: The review process for this paper was fully handled by C. Weber, Editor in Chief.

Listed in the Supplementary Online Appendix Material which is available online at www.thrombosis-online.com.

Keywords

Atrial fibrillation - ABI - ARAPACIS - myocardial infarction - vascular events

Full Text

References

References
1 Mozaffarian D, Benjamin EJ, Go AS. et al. Heart Disease and Stroke Statistics-2015 Update: A Report From the American Heart Association. Circulation 2015; 131: e29-e322.
2 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
3 Polimeni L, Perri L, Saliola M. et al. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med 2010; 05: 91-94.
4 Chao TF, Huang YC, Liu CJ. et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 2014; 11: 1941-1947.
5 Psaty BM, Manolio TA, Kuller LH. et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
6 Hughes M, Lip GY. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
7 Zabalgoitia M, Halperin JL, Pearce LA. et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31: 1622-1626.
8 Perlstein TS, Creager MA. The ankle-brachial index as a biomarker of cardiovascular risk: it’s not just about the legs. Circulation 2009; 120: 2033-2035.
9 Violi F, Lip GY, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med 2012; 07: 213-218.
10 Aboyans V, Criqui MH, Abraham P. et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126: 2890-2909.
11 Grenon SM, Gagnon J, Hsiang Y. Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease. N Engl J Med 2009; 361: e40.
12 Diehm C, Allenberg JR, Pittrow D. et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053-2061.
13 Ankle Brachial Index Collaboration. Fowkes FG, Murray GD. et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. J Am Med Assoc 2008; 300: 197-208.
14 Raparelli V, Proietti M, Napoleone L. et al. Asymptomatic peripheral artery disease and antiplatelet management. Vasa 2014; 43: 309-325.
15 Violi F, Daví G, Hiatt W. et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol 2013; 62: 2255-2256.
16 Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005; 25: 1463-1469.
17 Jones WS, Patel MR, Rockman CB, Guo Y, Adelman M, Riles T, Berger JS. Association of the ankle-brachial index with history of myocardial infarction and stroke. Am Heart J 2014; 167: 499-505.
18 Raparelli V, Proietti M, Buttä C. et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med 2014; 09: 861-870.
19 Wann LS, Curtis AB, January CT. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-123.
20 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
21 Violi F, Daví G, Hiatt W. et al. Reply: ankle-brachial index in patients with non-valvular atrial fibrillation. J Am Coll Cardiol 2014; 63: 1457-1458.
22 Thygesen K, Alpert JS, White HD. et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
23 Special report from the National Institute of Neurological Disorders and Stroke Classification of cerebrovascular diseases III. Stroke 1990; 21: 637-676.
24 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
25 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
26 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
27 Kamp O, Verhorst PM, Welling RC. et al. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J 1999; 20: 979-985.
28 Proietti M, Calvieri C, Malatino L. et al. Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. Atherosclerosis 2015; 238: 350-355.
29 Criqui MH, McClelland RL, McDermott MM. et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 56: 1506-1512.
30 Jones WS, Hellkamp AS, Halperin J. et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014; 35: 242-249.
31 Soliman EZ, Safford MM, Muntner P. et al. Atrial fibrillation and the risk of myocardial infarction. J Am Med Assoc Intern Med 2014; 174: 107-114.
32 Roldán V, Marín F, Fernández H. et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013; 111: 1159-1164.
33 Soliman EZ, Lopez F, O’Neal WT. et al. Atrial Fibrillation and Risk of ST-Segment Elevation versus Non-ST Segment Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2015; 131: 1843-1850.
34 Vermond RA, Van Gelder IC, Crijns HJ, Rienstra M. Does Myocardial Infarction Beget Atrial Fibrillation and Atrial Fibrillation Beget Myocardial Infarction?. Circulation 2015; 131: 1824-1826.
35 Gamra H, Murin J, Chiang CE. et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 2014; 107: 77-87.
36 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in at-rial fibrillation: a systematic review. Am J Med 2010; 123: 638-645 e4.
37 Armstrong EJ, Chen DC, Westin GG. et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 03: e000697.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)